Is there a pill form of Wegovy, and can you get it in the UK?

How the trial data shaped the approval of an oral semaglutide for weight loss

The MHRA's decision rested primarily on the OASIS 4 phase 3 trial: 307 adults with obesity or overweight plus at least one weight-related condition, no diabetes, followed for 64 weeks. Participants on oral semaglutide lost around 13.6% of body weight on average compared with roughly 2.4% in the placebo group, both groups alongside lifestyle changes. Among those who adhered fully to treatment throughout the trial, the average loss reached approximately 17%, though that figure only applies to that specific group and should not be taken as a general expectation.

Gastrointestinal side effects were the most common finding: 74% of participants on the tablet reported them versus 42% in the placebo group. These were generally mild to moderate and tended to settle over time, consistent with the pattern seen with GLP-1 medicines broadly. The MHRA's approval announcement described this as a significant step, and the NHS medicines page for semaglutide covers the general side-effect profile in plain language.

What OASIS 4 established clearly is that a pill form of semaglutide can produce meaningful weight reduction. Whether the tablet or the injection suits you better depends on factors a prescriber weighs individually (absorption, tolerability, daily routine) not on a blanket preference for one format.

What the dosing schedule for the Wegovy tablet actually looks like

The tablet schedule starts at 1.5 mg once daily, escalating through 4 mg and 9 mg to a 25 mg maintenance dose, spending at least one month at each level. That escalation exists to let your body adjust gradually; the early doses are not therapeutic targets in themselves.

There is an important distinction worth flagging here. Rybelsus (also oral semaglutide) comes in 3 mg, 7 mg and 14 mg strengths and is licensed for type 2 diabetes, not weight management. If you come across references to those strengths in a weight-loss context, they belong to a different product with a different licence. The Wegovy weight-loss tablet steps are 1.5 mg, 4 mg, 9 mg and 25 mg only. Confusing the two is surprisingly common, so it is worth being clear on this before discussing options with a prescriber. You can read more detail about the Wegovy pill's format and schedule if you want to go deeper on this before a consultation.

One practical point: the tablet is taken first thing in the morning on an empty stomach with a small amount of plain water, no more than around 120 ml. You wait at least 30 minutes before eating, drinking anything else (including coffee) or taking other oral medicines. For anyone whose morning is tightly scheduled, building this into a routine early matters. If your week tends to start more smoothly than it ends, Monday orders placed by midday can help keep supply consistent.

Who the Wegovy tablet is licensed for, and what it does not cover

The MHRA licensed the Wegovy tablet for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. It is not licensed for people under 18, and it is not recommended during pregnancy, breastfeeding or for anyone trying to conceive. Those exclusions apply to all semaglutide weight-loss formulations.

There is currently no NICE appraisal of the Wegovy tablet, which means it is not available on the NHS at the time of writing (as of summer 2026). A NICE technology appraisal would be required before NHS commissioning could begin. For now, access is through private prescription only, following a clinical assessment by a registered prescriber. Information on what private treatment through this route typically costs is available separately, and specific considerations for women including contraception and HRT interactions are worth reviewing before starting.

If you are already established on the 2.4 mg weekly injection and want to consider switching to the tablet, the prescribing guidance indicates that patients at 2.4 mg may move directly to the 25 mg tablet, but only following a clinical assessment, not as a self-directed change. The broader semaglutide tablet question and how it relates to both Wegovy and Rybelsus is covered on a dedicated page if you want background before that conversation.

Storage, travel and daily practicalities that make the tablet different from the pen

The most immediate practical difference between the tablet and the injection is storage. The Wegovy pen requires refrigeration at 2 to 8°C. The tablet does not. That matters for anyone who travels frequently, lives somewhere without reliable cold storage, or simply finds managing fridge space for medicines inconvenient.

There are no needles, no sharps disposal requirements and no injection technique to learn. For people who have been weighing up the injection primarily because of needle anxiety, the existence of a pill version of Wegovy changes the calculation. That said, bioavailability for oral semaglutide is lower than for the injection, the SNAC absorption enhancer compensates for this, which is partly why the maintenance dose of 25 mg in tablet form is so much higher by weight than the 2.4 mg weekly injection dose. The clinical outcomes in the trial are the relevant comparison, not the milligram number.

The question of whether Wegovy pills are available and how to access them through a regulated UK pharmacy is one our prescribers at nume are well placed to discuss. If you want to understand your options and whether the tablet or the injection is more likely to suit your circumstances, the right next step is a clinical conversation rather than a format preference chosen in isolation.

To talk through whether Wegovy tablets are appropriate for you, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.